Carcinoma in situ of oropharynx

Summary

Carcinoma in situ of oropharynx (MONDO:0021298) is a cancer and 2 clinical trials. Top therapeutic interventions include contusugene ladenovec. A subtype of pharynx carcinoma in situ — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinoma in situ of oropharynx
Mondo ID	MONDO:0021298
ICD-11	364791852
NCIT	C4590
SNOMED CT	92668003
UMLS	C0347099
MedGen	83852
GARD	0027885
Anatomy (UBERON)	UBERON:0001729
Is cancer (heuristic)	yes

Also known as: carcinoma in situ of oropharynx · carcinoma in situ of the oropharynx · oropharyngeal cancer stage 0 · oropharyngeal carcinoma in situ · oropharynx carcinoma in situ · oropharynx in situ carcinoma · stage 0 carcinoma of oropharynx · stage 0 carcinoma of the oropharynx · stage 0 oropharyngeal cancer · stage 0 oropharyngeal carcinoma · stage 0 oropharyngeal carcinoma aJCC v6 · stage 0 oropharyngeal carcinoma aJCC v6 and v7 · stage 0 oropharyngeal carcinoma aJCC v7 · stage 0 oropharyngeal carcinoma in situ · stage 0 oropharyngeal throat cancer · stage 0 oropharynx carcinoma

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › pharynx carcinoma in situ › carcinoma in situ of oropharynx

Related subtypes (2): carcinoma in situ of hypopharynx, carcinoma in situ of nasopharynx

Subtypes (1): carcinoma in situ of epiglottis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00064103	PHASE1/PHASE2	COMPLETED	Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
NCT01469429	PHASE1/PHASE2	COMPLETED	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CONTUSUGENE LADENOVEC	2	1